Abstracts
HT4 PRAGMATIC CLINICAL TRIALS FOR DRUG APPROVAL: IS IT REALISTIC?
Mohr P 1 , Sonnad S 2 , Mullins CD 3 , Whicher D 1 , Goldsack J 2 , Tunis SR 1 1 Center for Medical Technology Policy, Baltimore, MD, USA, 2 University of Pennsylvania, Philadelphia, PA, USA, 3 University of Maryland School of Pharmacy, Baltimore, MD, USA BACKGROUND: Patients, clinicians, payers and policymakers increasingly are interested in understanding comparative "real world" effectiveness of pharmaceutical products, often noting that traditional clinical trials performed for regulatory approval may not address important questions about the full range of benefits and harms of new drugs used in typical clinical settings. While more pragmatic designs are used for post-marketing studies, to date, no group formally has considered their utility and feasibility for regulatory approval trials. METHODS: In 2009, the Center for Medical Technology Policy convened an expert stakeholder working group to characterize recurring gaps in evidence that generally are not addressed in regulatory trials, explore the reasons for those shortcomings, and generate ideas for improving methods to make these trials more informative for patient and physician choices and reimbursement and coverage decisions. The working group included representatives from pharmaceutical companies, regulatory bodies, private and public payers, academics, consumers, and technology assessment organizations. Using discussions from this meeting and continued engagement of the working group over time, we developed a conceptual, methodological and policy framework to improve the design and implementation of pragmatic regulatory trials. RESULTS: There emerged greater than anticipated consensus among the regulators and payers participating in the working group that some pragmatic features are desirable and feasible to include in regulatory trials. The working group developed eight basic principles for making regulatory trials more pragmatic, covering the engagement of post-regulatory decision makers early in the design process to methods for designing more efficient trials. CONCLUSIONS: The optimal approach to pragmatic trials may not involve incorporating all possible pragmatic features, as are typically associated with large, simple trials. Some domains of pragmatism are more important to payers than others and any incremental movement toward more pragmatic designs may be not only highly valuable, but feasible.
PODIUM SESSION I: RESEARCH ON PRO METHODS (INCLUDING UTILITIES)

PR1 INCORPORATING TARIFF-LEVEL UNCERTAINTY AROUND ESTIMATES FROM THE CATALOGUE OF EQ-5D SCORES
Sullivan P 1 , Ghushchyan VH 2 , Slejko JF 2 1 Regis University School of Pharmacy, Denver, CO, USA, 2 University of Colorado Denver, Aurora, CO, USA OBJECTIVES: Analysts typically take as "fixed" the underlying tariff scoring function of a given utility instrument when conducting probabilistic sensitivity analysis, ignoring an important source of uncertainty. An "off-the-shelf" catalogue of EQ-5D scores from a nationally representative U.S. population has recently been published. The current study aims to incorporate the uncertainty in the underlying U.S. EQ-5D tariff function by estimating confidence intervals around estimates from the catalogue. METHODS: The Medical Expenditure Panel Survey (MEPS), a general population survey in the U.S., was pooled (2000, 2001, 2002 and 2003) to create a sample of 79,524 adults with valid EQ-5D responses. Chronic conditions were classified by ICD-9 codes and Clinical Classification Category (CCC) codes. Censored least absolute deviations (CLAD) regression methods were used to estimate the marginal disutility of each condition controlling for age, comorbidity, gender, race, ethnicity, income and education. US tariffs for the EQ-5D (Shaw) were applied to questionnaire responses. However, instead of taking the US EQ-5D tariff as a "fixed" function of the questionnaire responses, 500 bootstraps were conducted drawing from a distribution of possible EQ-5D tariffs based on the standard errors from the original scoring estimation. RESULTS: A catalogue of marginal disutility (EQ-5D) scores for each chronic ICD-9 and CCC code were estimated 500 times based on the distribution of possible EQ-5D tariffs. The 95% range of these potential marginal disutilities is presented and compared. CONCLUSIONS: Scores and marginal disutilities for a wide variety of chronic ICD-9 and CCC codes can be used to estimate QALYs in costeffectiveness analyses. This research provides a range of values around each marginal disutility in the catalogue of "off-the-shelf" EQ-5D scores. Uncertainty in the underlying US EQ-5D estimation tariff is incorporated in these ranges to encourage better understanding of the inherent uncertainty in EQ-5D estimates and to facilitate future probabilistic sensitivity analyses.
PR2 EVALUATING THE MEASUREMENT PROPERTIES OF AN AUGMENTED EQ-5D WITH THE INCLUSION OF TWO SINGLE QUALITY-OF-LIFE (QOL) INDICATORS USING THE MEDICAL EXPENDITURE PANEL SURVEY (MEPS)
Gu NY 1 , Bond TG 2 , Craig BM 3 1 Pharmerit North America, LLC, Bethesda, MD, USA, 2 James Cook University, Townsville, QLD, Australia, 3 Moffitt Cancer Center, Tampa, FL, USA OBJECTIVES: To evaluate the measurement properties of the EQ-5D profile augmented with its 0-100 mm visual analogue scale (VAS) and a 5-point summary selfrating of health (SRH). METHODS: We used data from 4,001 adults from the 2003 MEPS who had ≥1 of 7 most prevalent chronic conditions and completed the EQ-5D, VAS, and SRH. The original 101 VAS categories were collapsed into a 9-category item with sufficient responses in each category. Five SRH categories included "excellent", "very good", "good", "fair" and "poor". The Rasch rating scale and partial credit models were used to calibrate the EQ-5D and the single items, respectively. Calibrations were conducted using 4 different combinations: EQ-5D alone; EQ-5D+SRH; EQ-5D+VAS, and EQ-5D+SRH+VAS. Model goodness-of-fit was assessed in each disease group using INFIT mean squares (≤1.40). Principal Component Analysis of Rasch Residuals was used to confirm dimensionality examining the proportion of total variance explained by Rasch scale, person measures and item measures, respectively. RESULTS: Respondents were predominantly white, female, middle aged and suffered most commonly from hypertension (32%), diabetes (17%) and depression (15%). EQ-5D item "anxiety/depression" consistently showed misfit to the model across 7 conditions when EQ-5D was evaluated alone. The inclusion of VAS and/or SRH not only improved model fit, but also increased overall variances explained, and improved overall distribution of persons and items along the latent health trait. Specifically, when both items were included, 4 groups showed good model fit (mean squares ≤1.40). Consistently across all groups, VAS captured more person measures while SRH captured more item measures. CONCLUSIONS: The EQ-5D's measurement qualities are enhanced by the inclusion of VAS/SRH, which captures integral aspect of self-valuations on health that are possibly overlooked by the EQ-5D. The EQ-5D+VAS+SRH may serve as a suitable measurement framework for deriving population preference-weights. Consequently, a new valuation algorithm is called for.
PR3 NATIONAL CULTURE AND EQ-5D VALUE SETS
Bailey H 1 , Kind P 2 1 The University of the West Indies, Maracas Valley, Trinidad and Tobago, 2 University of York, York, UK Background Despite the growing importance of the EQ-5D descriptive system as a basis for the valuation of QALYs in cost-utility analysis, for most countries there are no EQ-5D social value sets. Researchers and policy makers wishing to use the EQ-5D descriptive system in a country for which there is no value set are advised to use one from a nearby or 'similar' population. Factors other than geographic proximity can affect the relative values of EQ-5D states. Objective This study explores the links
